Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $460000.0.

  • C4 Therapeutics' Depreciation & Amortization (CF) rose 407.24% to $460000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 1374.43%. This contributed to the annual value of $1.8 million for FY2024, which is 329.79% down from last year.
  • Latest data reveals that C4 Therapeutics reported Depreciation & Amortization (CF) of $460000.0 as of Q3 2025, which was up 407.24% from $615000.0 recorded in Q2 2025.
  • C4 Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $615000.0 for Q2 2025, and its period low was $305000.0 during Q1 2022.
  • For the 5-year period, C4 Therapeutics' Depreciation & Amortization (CF) averaged around $441947.4, with its median value being $448000.0 (2024).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first plummeted by 3237.25% in 2022, then skyrocketed by 7868.85% in 2023.
  • Quarter analysis of 5 years shows C4 Therapeutics' Depreciation & Amortization (CF) stood at $323000.0 in 2021, then surged by 61.3% to $521000.0 in 2022, then fell by 17.47% to $430000.0 in 2023, then grew by 11.63% to $480000.0 in 2024, then decreased by 4.17% to $460000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $460000.0 in Q3 2025, compared to $615000.0 in Q2 2025 and $456000.0 in Q1 2025.